Skip to Main Content

Advertisement

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/health/pharma/novartis-to-buy-myricx-bio-for-up-to-1-5-billion-6e8ee865

Novartis to Buy Myricx Bio for Up to $1.5 Billion

Myricx Bio is developing new antibody-drug conjugates for fighting cancer

By

Aimee Look


Listen

(2 min)

A view of the Novartis booth and logo at the BIO International Convention 2026.Novartis will pay $1.1 billion upfront for Myricx Bio, with up to $400 million in potential additional payments.Mike Blake/Reuters

Novartis NOVN-2.33%decrease; down pointing triangle said it agreed to pay up to $1.5 billion for Myricx Bio, in a bid to bolster its portfolio amid industry competition for oncology drugs.

The Swiss pharmaceutical company said it would purchase the privately held U.K.-based biotechnology firm, which is developing a new class of antibody-drug conjugates. Myricx Bio’s approach delivers differentiated cancer-killing mechanisms directly to tumor cells, Novartis said.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8


Videos


Most Popular News


Most Popular

OPINION


Further Reading

The U.K. Monarchy Is Getting a Big Funding Bump. Here’s How They’re Spending It.

‘The Masquerade’ Review: The Delights of Disguise

U.S. to Remove Tariffs on Scotch Whisky After King Charles-Trump Meeting

What Brings Feuding Americans Together? A King, It Turns Out

Jeff Bezos and Tim Cook Among Guests at State Dinner Honoring King Charles III and Queen Camilla

Advertisement

Read Original at WSJ